Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT1A1 | P22309 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.52 |
| ▸ | PSEN1 | P49768 | 10/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 10/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 10/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 10/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 10/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 10/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368500 | 0.93 | UGT1A1 (0.51) | UGT1A1KCNH2SLCO1B1PSEN1PSEN2 | |
| SCHEMBL18023082 | 0.91 | UGT1A1 (0.54) | UGT1A1KCNH2SLCO1B1PSEN1PSEN2 | |
| SCHEMBL10279333 | 0.90 | UGT1A1 (0.53) | UGT1A1KCNH2SLCO1B1PSEN1PSEN2 | |
| SCHEMBL367898 | 0.88 | UGT1A1 (0.49) | UGT1A1KCNH2SLCO1B1PSEN1PSEN2 | |
| SCHEMBL369451 | 0.84 | UGT1A1 (0.48) | UGT1A1KCNH2SLCO1B1PSEN1PSEN2 | |
| SCHEMBL10356245 | 0.83 | UGT1A1 (0.51) | UGT1A1KCNH2SLCO1B1PSEN1PSEN2 | |
| SCHEMBL369543 | 0.81 | UGT1A1 (0.48) | UGT1A1KCNH2SLCO1B1PSEN1PSEN2 | |
| SCHEMBL360429 | 0.80 | ACHE (0.37) | UGT1A1KCNH2SLCO1B1PSEN1PSEN2 | |
| SCHEMBL10352841 | 0.79 | UGT1A1 (0.33) | UGT1A1KCNH2SLCO1B1 | |
| SCHEMBL18023089 | 0.77 | UGT1A1 (0.38) | UGT1A1KCNH2SLCO1B1PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637523-B2 | Compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637523-B2 | Compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-07-19 | — | — | US | disclosed |
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | UGT1A1 2634/4885KCNH2 4384/4885SLCO1B1 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.